Apr. 9 at 9:55 PM
$HOWL anyone who’s looked into this deeper can help with your view on potential outcome. I see Lynx upped its shares and is known for catalyst strat alt plays for biotechs. At the same time stock trades at net cash with 32M market cap, while 57M cash and 28M debts. But Jazz milestone payment in future of 1.2B for WTX - but not de risked yet as early stage and also lower NPV in a price valuation. Plus 2 additional assets in Phase 1. I can see a potential 2-3X if things go well, but since market overcrowded and all early stage with high failure rate still, it may likely be 1.5… but then how deep can it fall if it already trades at cash? Views appreciated!
